Abstract 15537: Human Induced Pluripotent Stem Cell Derived Cardiomyocytes (hiPSC-CM) Showed Similar Potency as Human Mesenchymal Stem Cells (hMSC) in Treating Myocardial Infarction
Introduction: Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) have recently been shown to express key cardiac proteins and improve in vivo cardiac function when administered following myocardial infarction. However, the efficacy of hiPSC-derived cell therapies, in direct comparison to current, well-established stem cell-based therapies, is yet to be elucidated. The objective of the current study was to compare the therapeutic efficacy of hiPSC-CM with human mesenchymal stem cells (hMSC) in mitigating myocardial infarction (MI) outcome.
Methods: Male athymic rats were subjected to permanent ligation of the left-anterior-descending (LAD) coronary artery to induce acute MI. Four experimental groups were studied: 1) control (non-MI), 2) MI, 3) hMSC (MI+MSC), and 4) hiPSC-CM (MI+hiPSC-derived cardiomyocytes). Cells were injected into the ischemic heart 30-min after LAD ligation. The hiPSC and hMSC were labeled with super-paramagnetic iron oxide (SPIO) in vitro to track the transplanted cells in the ischemic heart by high-field cardiac MRI. Echocardiography (M-mode) was performed to evaluate the cardiac function and histological studies and western blot experiments were performed to assess the cell engraftment and protein expression in all groups.
Results: At four-weeks after MI, MRI imaging showed engraftment of hiPSC-CM and hMSC in the hearts (Figure 1). Echocardiography showed a significant improvement of cardiac function in the hiPSC-CM and hMSC groups, when compared to MI. Immunohistological studies showed expression of connexin-43, alpha-actinin and myosin heavy chain in engrafted hiPSC-CM. Western blot data showed an increase in p-ERK and cardiac troponin-I in the hiPSC-CM and hMSC compared with the MI group.
Conclusions: hiPSC-CM showed increased expression of cardiac markers and improvement in cardiac function comparable to hMSC following MI.
- © 2013 by American Heart Association, Inc.